SpainSpain

Spain

07.06.2004

Madrid - Spanish-based PharmaMar announced at the beginning of May that it has commenced a phase-II trial of Aplidin®, a novel marine anti-tumour agent derived from the marine tunicate Aplidium albicans, in small cell lung carcinoma. This phase-II trial is a multi-centre (European Union and the United States), open label study in patients who have relapsed or progressed after first line chemotherapy. The primary end point of the trial is the response rate. Secondary objectives are to evaluate the pharmacokinetics and further investigate the safety profile of the product.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/spain-23.html

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR303.8%
  • SANTHERA (CH)68.90 CHF102.6%
  • ADDEX (CH)4.06 CHF82.1%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-29.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)68.90 CHF3433.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP769.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)9.69 EUR-69.2%

No liability assumed, Date: 23.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events